CRISPR has received a regulatory green light in what could be the first clinical trial with the “scientific discovery of the century”. It’ll be used to improve cancer cell therapies.
CRISPR has already revolutionized biotech, quickly overtaking the field of gene editing. It also has immense potential in the therapeutic field, so it’s not surprising there’s a lot of interest, not to mention its famous patent war.
What may be surprising is the amount of money involved, with $120M mega-rounds by Editas Medicine (US), plus $70M for Intellia (US) and €79.5M for CRISPR Therapeutics (Switzerland). That’s a lot of money for something without any clinical data! ( a topic brought up during the CRISPR fireside chat at Refresh…)
This clinical data is now one step closer to reality as the US National Institutes of Health (NIH) approved a study proposal to use CRISPR/Cas9 technology to improve cancer cell therapies. While it still needs FDA approval,